Welcome to our dedicated page for Charles River Laboratories International news (Ticker: CRL), a resource for investors and traders seeking the latest updates and insights on Charles River Laboratories International stock.
Founded in 1947, Charles River Laboratories International, Inc. (symbol: CRL) is a global leader in providing essential products and services to pharmaceutical and biotechnology companies, government agencies, and academic institutions. The company's mission is to accelerate research and drug development efforts, significantly contributing to the healthcare industry.
Charles River operates through three main segments:
- Research Models & Services: This segment is renowned for being the leading provider of laboratory animal models. Charles River breeds and supplies animals with specific genetic traits for preclinical studies worldwide, supporting the critical early stages of drug discovery.
- Discovery & Safety Assessment: This segment offers a comprehensive range of services necessary for the early development of new drugs. From discovery services to safety assessments, Charles River helps clients navigate the complex process of taking a drug from concept to early-stage development.
- Manufacturing Support: This includes microbial solutions for in vitro testing, biologics testing services, and avian vaccine services. These services are integral to ensuring the safe manufacture and quality control of new therapies.
The company's workforce is dedicated to providing clients with the expertise and services they need to improve and expedite the discovery and development of new therapies. Charles River's collaborative approach and commitment to excellence have established it as a trusted partner in the life sciences industry.
Charles River continues to innovate and expand its services, making significant strides in the fields of drug discovery, biotechnology, and pharmaceuticals. With a strong financial footing and strategic partnerships, the company is well-positioned to support the future of healthcare advancements globally.
Rhea-AI Summary
Charles River Laboratories International, Inc. (NYSE: CRL) is set to release its fourth-quarter and full-year 2023 financial results and provide 2024 guidance on February 14th. A conference call will be held at 8:30 a.m. ET on the same day to discuss the information. Investors can listen to a live webcast through the Company's website and access a replay afterward.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
-
News
Rhea-AI Summary
Charles River Laboratories International, Inc. (NYSE: CRL) has launched off-the-shelf Rep/Cap plasmid offering to streamline adeno-associated virus (AAV)-based gene therapy programs, reducing manufacturing effort by up to 66%. The ready-to-use plasmid products are produced and released according to batch production records, with CMC guidance and a Certificate of Analysis (COA) to support Investigational New Drug (IND) and Clinical Trial Application (CTA) filing. The launch will take place at Advanced Therapies Week, January 16-19, at the Miami Beach Convention Center.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.39%
Tags
-
Rhea-AI Summary
Charles River Laboratories International, Inc. (NYSE: CRL) will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9th, discussing strategic focus, business developments, and recent trends. A live webcast and replay will be available on the Investor Relations section of the Charles River website at ir.criver.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.36%
Tags
Rhea-AI Summary
Charles River Laboratories International, Inc. (NYSE: CRL) has achieved a significant milestone in their collaboration with Vertex to manufacture CASGEVY™, the world’s first gene-edited therapy targeting severe sickle cell disease. The Memphis facility received regulatory approval from the FDA and HPRA to commercially manufacture an allogeneic cell therapy drug product. This approval enables Charles River to work with Vertex to help bring this groundbreaking treatment to patients suffering from severe sickle cell disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
-
Rhea-AI Summary
Charles River Laboratories International, Inc. (NYSE: CRL) has entered into an agreement with CELLphenomics, a biotechnology company using 3D hydrogel technology to advance the understanding of the tumor microenvironment and predict therapeutic efficacy. CELLphenomics’ proprietary 3D tumor model platform, PD3D®, will expand Charles River’s 3D in vitro testing services to optimize oncological approaches for clients. The platform provides reliable, predictive preclinical PD3D models that recapitulate the biological properties of the donor tissue, including key histopathological features and genomic makeup. CELLphenomics’ continuously growing biobank comprises more than 500 complex in vitro models from over 20 tumor entities, offering the world’s largest collection of complex in vitro models of rare and ultra-rare tumors. Leveraging CELLphenomics technology, Charles River will have a novel in vitro option for identifying therapeutics for rare and ultra-rare disease types, with full access to Charles River’s impressive biobank and data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.05%
Tags
-
Rhea-AI Summary
Charles River Laboratories International, Inc. (CRL) partners with Genetic Cures for Kids Inc (GC4K) to produce plasmid DNA for early phase trials of gene therapy for Hereditary Spastic Paraplegia Type 56 (SPG56), a rare neurodegenerative disease. SPG56 affects motor and cognitive functions and currently has no treatment. GC4K aims to develop a gene therapy not only for SPG56 but also as a model for treating other rare genetic diseases. Charles River's eXpDNA™ platform and HQ Plasmid Manufacturing Center of Excellence will support GC4K's mission by providing high-quality plasmid DNA production services.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
Rhea-AI Summary
Charles River Laboratories International, Inc. (CRL) will present at the 6th Annual Evercore ISI HealthCONx Conference on November 29th, discussing strategic focus, business developments, and recent trends. The presentation will be available via live webcast and replay on the Investor Relations section of their website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
-
Rhea-AI Summary
Charles River Laboratories International, Inc. (NYSE: CRL) expands its CliniPrime™ suite with the launch of CliniPrime Cryopreserved Leukopaks for gene-modified cell therapy development and manufacturing. Cryopreserved leukopaks play a critical role in research and development, maximizing cellular viability, consistency, and long-term availability. The new offering aims to meet the growing industry need for reliable and consistent sources of cellular starting material, supporting both clinical trial development and commercialization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
-
Rhea-AI Summary
Charles River Laboratories International, Inc. (NYSE: CRL) and Aitia announce a strategic partnership focused on co-developing patient-derived xenograft (PDX) Digital Twins for in vivo oncology research. Aitia will deploy Charles River's AI-powered drug solution platform, Logica, to optimize the discovery and early development of therapeutic programs for neurodegenerative disease and oncology. The agreement also includes the development of a PDX Digital Twin to predict the best tumor models for in vivo oncology research. Charles River has made an equity investment in Aitia as part of the partnership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
News
Rhea-AI Summary
Charles River Laboratories International, Inc. (NYSE: CRL) to Present 19 Scientific Posters at Neuroscience 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.69%
Tags
FAQ
What is the current stock price of Charles River Laboratories International (CRL)?
The current stock price of Charles River Laboratories International (CRL) is $195.77 as of November 22, 2024.
What is the market cap of Charles River Laboratories International (CRL)?
The market cap of Charles River Laboratories International (CRL) is approximately 10.6B.
What services does Charles River Laboratories provide?
Charles River provides research models, discovery and safety assessment services, and manufacturing support, including microbial solutions, biologics testing, and avian vaccine services.
When was Charles River Laboratories founded?
Charles River Laboratories was founded in 1947.
Who are Charles River Laboratories' primary clients?
The company's primary clients are pharmaceutical and biotechnology companies, government agencies, and leading academic institutions.
What is Charles River Laboratories' mission?
Charles River's mission is to accelerate research and drug development efforts globally.
What is included in the Research Models & Services segment?
This segment includes providing laboratory animal models with specific genetic traits for preclinical studies.
What does the Discovery & Safety Assessment segment offer?
This segment offers services for the early development of new drugs, including discovery services and safety assessments.
What are some of the services provided under Manufacturing Support?
Manufacturing Support includes microbial solutions for in vitro testing, biologics testing services, and avian vaccine services.
How does Charles River contribute to the healthcare industry?
Charles River helps expedite the discovery and development of new therapies, aiding in research and the safe manufacture of new drugs.
What makes Charles River Laboratories a trusted partner in the life sciences industry?
The company's commitment to excellence, innovative approach, and comprehensive service offerings make it a trusted partner.
What is the ticker symbol for Charles River Laboratories International, Inc.?
The ticker symbol for Charles River Laboratories International, Inc. is CRL.
Charles River Laboratories International, Inc.
NYSE:CRL
CRL Rankings
CRL Stock Data
10.63B
50.64M
0.92%
103.97%
3.62%
Diagnostics & Research
Services-commercial Physical & Biological Research
United States of America
WILMINGTON